Biochemical parameters of the functional state liver in patients with hepatitis Under conditions of SARS-CoV-2 coinfection

D. Krenytska, A. Rachkovska, O. Savchuk, V. Karbovskiy
Taras Shevchenko National University of Kyiv, Kyiv; Taras Shevchenko National University of Kyiv, Kyiv; Taras Shevchenko National University of Kyiv, Kyiv; LLC "Biopharma plazma", Bila Tserkva


The COVID-19 pandemic started at the end of 2019 in China. It is spreading to all continents in a few months and continuing to this day. It shows a serious threat to the healthcare system around the world, because it is necessary to provide intensive care to a previously unthinkable number of patients. Although SARS-CoV-2 causes damage to the respiratory system, research shows that COVID-19 is a hidden enemy for our body, as a result of which other organs also suffer, in particular the liver. In the literature, over a short period of the pandemic, little scientific information has accumulated regarding changes in the biochemical parameters of the liver during the development of COVID-19. Our study focused on the clinical diagnosis of patients suffering from hepatitis B and infected with SARS-CoV-2, additionally, a study was conducted of persons suffering from COVID-19 and patients with the development of hepatitis B, and a comparison of the study groups was carried out to identify relationships. links between SARSCoV- 2 infection and HBV progression. We found that in patients with hepatitis B with SARS-CoV-2 coinfection, significant deviations from the physiological norm of such parameters of liver functioning as ALT, AST, total and direct bilirubin, were observed, however, such indicators as GGT were in the limit values of the norm. and alkaline phosphatase. Our study demonstrates the need for careful monitoring of patients with hepatitis B with SARS-CoV-2 coinfection, and it is also recommended to conduct additional clinical diagnosis of such groups of patients to identify other parameters of pathological conditions and to improve diagnostic/treatment approaches in high-risk groups of patients infected with SARS-CoV-2.


Hepatitis B; SARS-CoV-2; liver function tests

Full Text:



Shi Y., Wang G., Cai X.P., Deng J.W., Zheng L., Zhu H.H., Zheng M., Yang B., Chen Z. J. An overview of COVID-19. Journal of Zhejiang University Science. 2019; 21(5): 343-360. doi: 10.1631/jzus.B2000083.

XuZ., ShiL., WangY., ZhangJ. et al Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine. 2020; 8(4): 420-422. doi: 10.1016/S2213-2600(20)30076-X.

Jothimani D., Venugopal R., Abedin M.F., Kaliamoorthy I., Rela M.COVID-19 and the liver. Journal of Hepatology. 2020; 73(5): 1231-1240. doi: 10.1016/j.jhep.2020.06.006.

Chai X., Hu L., Zhang Y. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection. BioRxiv. 2020; 3(5): 1- 15. DOI: 10.1101/2020.02.03.931766.

Xu L., Liu J., Lu M., Yang D., Zheng X.Liver injury during highly pathogenic human coronavirus infections. Liver International. 2020; 40(5): 998-1004. doi: 10.1111/liv.14435.

Alqahtani S.A., Schattenberg J.M.Liver injury in COVID-19: The current evidence. United European Gastroenterol Journal. 2020; 8(5): 509- 519. doi: 10.1177/2050640620924157.

Napodano C., Pocino K., Stefanile A., et al COVID-19 and hepatic involvement: The liver as a main actor of the pandemic novel. Scandinavian Journal of Immunology.2021; 40(5): 23-37. doi: 10.1111/sji.12977.

Tian D., Ye Q.Hepatic complications of COVID-19 and its treatment. Journal of Medical Virology. 2020; 92(1): 1818-1824.

Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B.Hepatic complications of COVID-19 and its treatment. JAMA.2020; 323(18): 1824- 1836. doi: 10.1001/jama.2020.6019.

Licata A. Adverse drug reactions and organ damage: The liver. European Journal of Internal Medicine. 2016; 28: 9-16.

Marjot T., Webb G.J., Barritt A.S., et al COVID-19 and liver disease: mechanistic and clinical perspectives. Nature Reviews Gastroenterology & Hepatology. 2021; 18(5): 348-364. doi: 10.1038/s41575-021-00426-4.

Tian-Dan Xiang, Xin ZhengInteraction between hepatitis B virus and SARS-CoV-2 infections. World Journal of Gastroenterology. 2021; 27(9): 782-793. doi: 10.3748/wjg.v27.i9.782.

Chen L., Huang S., Yang J., et al Clinical characteristics in patients with SARS-CoV-2/HBV co-infection. Journal of Viral Hepatitis. 2020; 27(12): 1504-1507. doi: 10.1111/jvh.13362.

Liu J., Wang T., Cai Q., Sun L. et al Longitudinal changes of liver function and hepatitis B reactivation in COVID-19 patients with pre-existing chronic hepatitis B virus infection. Hepatology Research. 2020; 50(11): 1211- 1221. doi: 10.1111/hepr.13553.

Aldhaleei W.A., Alnuaimi A., Bhagavathula A.S.COVID-19 Induced Hepatitis B Virus Reactivation: A Novel Case From the United Arab Emirates. Cureus. 2020; 12(6): 27-43. doi: 10.7759/cureus.8645.

Chau T.N., Lee K.C., Yao H.SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology. 2020; 39(2): 302-310.

Lozano-Sepulveda S.A., Galan-Huerta K., et al SARS-CoV-2 another kind of liver aggressor, how does it do that? Annals of Hepatology. 2020; 19(6): 592-596. doi: 10.1016/j.aohep.2020.08.062.

Received in the editorial 14.09.2021

Received version on 14.10.2021

Signed in the press on 14.10.2021



  • There are currently no refbacks.

Лицензия Creative Commons
This journal is available according to the Creative Commons License «Attribution» («Атрибуція») 4.0 Global (CC-BY).